All In Biotech

Drug Trial Radar · NCT04864782

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

A Study of QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Jan 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

46

Actual

Start

Sep 23, 2020

Primary completion

Sep 30, 2022

Study completion Nov 1, 2023

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of PD-1 Inhibitor (QL1604) plus chemotherapy in patients with Stage IV, recurrent, or metastatic cervical cancer. Possible chemotherapy regimens include: paclitaxel plus cisplatin and paclitaxel plus carboplatin.

Conditions

  • Cervical Cancer

Interventions

  • QL1604Drug

    Intravenous Infusion

  • Paclitaxel injectionDrug

    Intravenous Infusion

  • Cisplatin/CarboplatinDrug

    Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with adverse eventsTime frame: Up to 90 days from last dose
  2. Objective response rate (ORR) as assessed by investigator based on RECIST v1.1 and iRECISTTime frame: approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.